Cancer and transplantation intersect at the mammalian target of rapamycin

Transplantation

Volumn 84, Issue 6, 2007, Pages 682-684

  MacDonald, Allan S ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Cumberland Regional Health Care Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CISPLATIN; CYCLIN D; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL DERIVATIVE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TRASTUZUMAB;

APOPTOSIS; CANCER REGRESSION; CELL CYCLE PROGRESSION; CELL DIVISION; CELL GROWTH; CYTOKINE RELEASE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG CANCER; LYMPHOMA; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VIRUS LOAD;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; ORGAN TRANSPLANTATION; PROTEIN KINASES; SIROLIMUS;

EID: 34748876548     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000280548.99241.c4     Document Type: Note

References (6)

1. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883.
2. Lebbe C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006; 6: 2164.
3. Sindhi R, Webber S, Venkatarainanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001; 72: 851.
4. Kneteman NM, Overholzer J, Al-Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301.
5. Campistol JM, Gutierrez-Dalman A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttranplantation Kaposi's sarcoma. Transplantation 2004; 77: 760.
6. Mathew T, Kreis H, Friend P. Two year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicentre studies. Clin Transplant 2004; 18: 446.